MedTrace Logo

Optimizing Vancomycin Therapy in Children

NCT05691309 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 29

Last updated 2024-12-20

Study results available
· View outcomes & findings →

Summary

The purpose of Opt Vanc is to evaluate the feasibility of Bayesian dose adaptation, based on a previously-developed population pharmacokinetic (PK) model and a single optimally timed PK sample, to predict vancomycin area under the curve (AUC) in critically ill children.

Conditions

Sponsors & Collaborators

Eligibility

Min Age
1 Year
Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-12-12
Primary Completion
2023-11-22
Completion
2023-11-22

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05691309 on ClinicalTrials.gov